Pasar al contenido principal

CARACTERIZACION OMICA EN ENFERMEDAD INFLAMATORIA INTESTINAL: PREDICTORES DE RIESGO PARA SENTAR LAS BASES PARA MEDICINA DE PRECISION

PID2019-108244RA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publicación Artículo científico (JournalArticle)

Mitochondrial Dysfunction: Unraveling the Elusive Biology Behind Anti-TNF Response During Ulcerative Colitis

  • Kioroglou, Dimitrios
  • Peña Cearra, Ainize
  • Corraliza, Ana M.
  • Seoane, Iratxe
  • Castelo, Janire
  • Panés, Julian
  • Gómez Irwin, Laura
  • Rodríguez Lago, Iago
  • Ortiz de Zárate, Jone
  • Fuertes Franco, Miguel
  • Martín Ruiz, Itziar
  • González, Monika
  • Aransay, Ana M.
  • Salas, Azucena
  • Rodriguez, Héctor
  • Anguita, Juan
  • Abecia, Leticia
  • Marigorta, Urko M.
[EN]Background: Recent studies hint at mitochondrial genes influencing UC patient response to anti-TNF treatment. We evaluated this hypothesis by following a targeted strategy to identify gene expression that captures the relationship between mitochondrial dysregulation and response to treatment. Our objective was to initially examine this relationship in colon samples and subsequently assess whether the resulting signal persists in the bloodstream. Methods: We analyzed the transcriptome of colon samples from an anti-TNF-treated murine model characterized by impaired mitochondrial activity and treatment resistance. We then transferred the findings that linked mitochondrial dysfunction and compromised treatment response to an anti-TNF-treated UC human cohort. We next matched differential expression in the blood using monocytes from the peripheral blood of controls and IBD patients, and we evaluated a classification process at baseline with whole blood samples from UC patients. Results: In human colon samples, the derived gene set from the murine model showed differential expression, primarily enriched metabolic pathways, and exhibited similar classification capacity as genes enriching inflammatory pathways. Moreover, the evaluation of the classification signal using blood samples from UC patients at baseline highlighted the involvement of mitochondrial homeostasis in treatment response. Conclusions: Our results highlight the involvement of metabolic pathways and mitochondrial homeostasis in determining treatment response and their ability to provide promising classification signals with detection levels in both the colon and the bloodstream., NO, This work was supported by grants from the Spanish Ministry of Science MCIN/AEI/10.13039/501100011033 (PID2019-108244RA-I00 to UMM, PID2021-124328OB-I00 to J.A., RYC2020-030632-I to U.M.M, CEX2021-001136-S to U.M.M and D.K),”La Caixa” Foundation (ID 100010434, fellowship code LCF/BQ/LI18/11630001 to U.M.M), V Grant from GETECCU-MSD (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis ulcerosa to L.A.). A.P.C. and I.S. are supported by fellowships from the University of the Basque Country (UPV/EHU) and the Basque Government, respectively.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY), study protocol for a prospective cohort study

  • Rodríguez-Lago, Iago|||0000-0003-1133-4578
  • Marigorta, Urko M
  • Mateos Muñoz, Beatriz|||0000-0003-0326-4119
  • Mañosa i Ciria, Míriam|||0000-0002-9051-2581
  • Márquez Mosquera, Lucía|||0000-0002-3182-9570
  • Menchén, Luis
  • Rodríguez-Moranta, Francisco
  • Alonso-Abreu, Inmaculada|||0000-0003-0406-029X
  • Aguas, Mariam|||0000-0003-4353-569X
  • Alonso-Galán, Horacio
  • Borràs, Pere A.|||0000-0001-6793-7592
  • Castro, Beatriz
  • Domènech, Eugeni|||0000-0002-2315-7196
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • de Francisco, Ruth|||0000-0001-8476-1672
  • García Alonso, Francisco Javier
  • García, Natalia
  • García-Bosch, Orlando
  • Gargallo-Puyuelo, C.J.|||0000-0002-3545-2707
  • P. Gisbert, Javier|||0000-0003-2090-3445
  • Iglesias-Flores, Eva
  • Mesonero, Francisco|||0000-0002-7864-8187
  • Ortiz de Zarate, Jone
  • Ramos López, Laura|||0000-0001-7015-1742
  • Sainz, Empar
  • Ladrón, Pablo
  • Suria, Carles
  • Suárez Ferrer, Cristina|||0000-0003-1789-3784
  • Tejido, Coral
  • Varela, Pilar|||0000-0003-1737-3236
  • Vicente, Raquel|||0000-0002-7605-3534
  • Zabana, Yamile|||0000-0003-4023-8868
  • Castany, Gisela
  • Rodríguez García, Eva
  • Gutiérrez Casbas, Ana|||0000-0002-5460-4139
  • Barreiro de-Acosta, Manuel|||0000-0001-5915-1477
The period prior to the diagnosis of inflammatory bowel disease (IBD), defined as the preclinical phase, has emerged as a potential target for disease modification strategies. Despite the relevance of an early diagnosis to the prognosis of the disease, only a limited number of patients are diagnosed during this window of opportunity. To determine the risk of developing symptoms after an incidental diagnosis of IBD and to describe the clinical, genetic, and immunological characteristics of IBD during its preclinical phase. This study protocol describes a prospective, multicenter cohort study in which incidental (i.e., asymptomatic) IBD within the colorectal cancer screening program will be characterized from a clinical and multi-omic perspective and compared with symptomatic patients and healthy non-IBD controls. Samples from blood, urine, stool, and intestinal endoscopic biopsies will be obtained at baseline. A second sample set will be obtained after 52 weeks from those who remain asymptomatic; samples will also be obtained in those with new-onset symptoms. Medical treatment will be prescribed in all patients following current guidelines. Follow-up visits will be performed every 6 months for 10 years, and all new-onset symptoms, changes in disease behavior, extraintestinal manifestations, IBD-related medical therapies, or surgeries will be recorded. Two control cohorts will be included: one including recently diagnosed symptomatic IBD patients (<3 months), and another with healthy non-IBD controls after a normal ileocolonoscopy, in whom samples will be obtained at baseline. Samples from patients and controls will undergo genetic, proteomic, transcriptomic, single-cell RNA sequencing, metabolomic, and microbiome analyses, and integration of data between the different omic perspectives will also be performed. The study has been approved by the Basque Country Ethics Committee (PI2021116). Conclusion: EARLY will generate a unique dataset addressing a previously unexplored area of IBD, with the final aim of describing the prognosis of patients from its earlier phases on the disease and integrating clinical and omic data into useful tools for the long-term prediction of disease outcomes.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

  • Rodríguez-Lago, Iago
  • Márquez Mosquera, Lucía
  • Barreiro-de Acosta, Manuel
Background: The period prior to the diagnosis of inflammatory bowel disease (IBD), defined as the preclinical phase, has emerged as a potential target for disease modification strategies. Despite the relevance of an early diagnosis to the prognosis of the disease, only a limited number of patients are diagnosed during this window of opportunity. Objectives: To determine the risk of developing symptoms after an incidental diagnosis of IBD and to describe the clinical, genetic, and immunological characteristics of IBD during its preclinical phase. Design: This study protocol describes a prospective, multicenter cohort study in which incidental (i.e., asymptomatic) IBD within the colorectal cancer screening program will be characterized from a clinical and multi-omic perspective and compared with symptomatic patients and healthy non-IBD controls. Methods: Samples from blood, urine, stool, and intestinal endoscopic biopsies will be obtained at baseline. A second sample set will be obtained after 52 weeks from those who remain asymptomatic; samples will also be obtained in those with new-onset symptoms. Medical treatment will be prescribed in all patients following current guidelines. Follow-up visits will be performed every 6 months for 10 years, and all new-onset symptoms, changes in disease behavior, extraintestinal manifestations, IBD-related medical therapies, or surgeries will be recorded. Two control cohorts will be included: one including recently diagnosed symptomatic IBD patients (<3 months), and another with healthy non-IBD controls after a normal ileocolonoscopy, in whom samples will be obtained at baseline. Samples from patients and controls will undergo genetic, proteomic, transcriptomic, single-cell RNA sequencing, metabolomic, and microbiome analyses, and integration of data between the different omic perspectives will also be performed. The study has been approved by the Basque Country Ethics Committee (PI2021116). Conclusion: EARLY will generate a unique dataset addressing a previously unexplored area of IBD, with the final aim of describing the prognosis of patients from its earlier phases on the disease and integrating clinical and omic data into useful tools for the long-term prediction of disease outcomes. Trial registration: NCT05698745., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: IR-L is funded by a research grant from Gobierno Vasco-Eusko Jaurlaritza (grant Nos. 202011106 and 2023222006). The EARLY study is funded by an IIS Grant from AbbVie, Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del sistema de I+D+i (PID2019-108244RA-I00), GETECCU-Pfizer grant, Ayudas a Proyectos de Investigación y Desarrollo en Salud del Departamento de Salud del Gobierno Vasco (2020111061), and the 10x Genomics Core Lab Grant Program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

  • Rodríguez-Lago, Iago
  • Márquez Mosquera, Lucía
  • Barreiro-de Acosta, Manuel
Background: The period prior to the diagnosis of inflammatory bowel disease (IBD), defined as the preclinical phase, has emerged as a potential target for disease modification strategies. Despite the relevance of an early diagnosis to the prognosis of the disease, only a limited number of patients are diagnosed during this window of opportunity. Objectives: To determine the risk of developing symptoms after an incidental diagnosis of IBD and to describe the clinical, genetic, and immunological characteristics of IBD during its preclinical phase. Design: This study protocol describes a prospective, multicenter cohort study in which incidental (i.e., asymptomatic) IBD within the colorectal cancer screening program will be characterized from a clinical and multi-omic perspective and compared with symptomatic patients and healthy non-IBD controls. Methods: Samples from blood, urine, stool, and intestinal endoscopic biopsies will be obtained at baseline. A second sample set will be obtained after 52 weeks from those who remain asymptomatic; samples will also be obtained in those with new-onset symptoms. Medical treatment will be prescribed in all patients following current guidelines. Follow-up visits will be performed every 6 months for 10 years, and all new-onset symptoms, changes in disease behavior, extraintestinal manifestations, IBD-related medical therapies, or surgeries will be recorded. Two control cohorts will be included: one including recently diagnosed symptomatic IBD patients (<3 months), and another with healthy non-IBD controls after a normal ileocolonoscopy, in whom samples will be obtained at baseline. Samples from patients and controls will undergo genetic, proteomic, transcriptomic, single-cell RNA sequencing, metabolomic, and microbiome analyses, and integration of data between the different omic perspectives will also be performed. The study has been approved by the Basque Country Ethics Committee (PI2021116). Conclusion: EARLY will generate a unique dataset addressing a previously unexplored area of IBD, with the final aim of describing the prognosis of patients from its earlier phases on the disease and integrating clinical and omic data into useful tools for the long-term prediction of disease outcomes. Trial registration: NCT05698745., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: IR-L is funded by a research grant from Gobierno Vasco-Eusko Jaurlaritza (grant Nos. 202011106 and 2023222006). The EARLY study is funded by an IIS Grant from AbbVie, Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del sistema de I+D+i (PID2019-108244RA-I00), GETECCU-Pfizer grant, Ayudas a Proyectos de Investigación y Desarrollo en Salud del Departamento de Salud del Gobierno Vasco (2020111061), and the 10x Genomics Core Lab Grant Program.